2. Search Result
Search Result
Results for "

rearrangement

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

2

Peptides

4

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112301A
    trans-Pralsetinib

    trans-BLU-667

    		 RET Cancer
    trans-Pralsetinib (trans-BLU-667) is a rearranged during transfection (RET) inhibitor extracted from patent US20170121312A1, Compound Example 129 .
    trans-Pralsetinib
  • HY-34595
    Pyrazoloadenine

    		RET Cancer
    Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity .
    Pyrazoloadenine
  • HY-151902
    SJ988497

    		PROTACs JAK Cancer
    SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .
    SJ988497
  • HY-N3458A
    Dugesin B

    (-)-Isosalvipuberulin; (-)-Isopuberulin

    		 Others Others
    Dugesin B ((-)-Isosalvipuberulin), is a rearranged clerodane diterpenoid, which can be isolated from the aerial parts of Salvia dugesii .
    Dugesin B
  • HY-145024
    RET-IN-6

    		RET Cancer
    RET-IN-6 is a potent RET (rearranged during transfection) inhibitor with an IC50 of 4.57 nM (CN113461670A, compound 321) .
    RET-IN-6
  • HY-136360
    MI-3454
    2 Publications Verification

    		 Epigenetic Reader Domain Cancer
    MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .
    MI-3454
  • HY-N1770
    12-Hydroxysapriparaquinone

    3,4-Didehydrosapriparaquione
    12-Hydroxysapriparaquinone (compound 8) is a rearranged 4,5-seco-abietane diterpenoid isolated from the petroleum ether extract of the root of Salvia rhytidea .
    12-Hydroxysapriparaquinone
  • HY-122698
    CCI-007

    		Apoptosis Cancer
    CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells .
    CCI-007
  • HY-144422
    RET-IN-15

    		RET Cancer
    RET-IN-15 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer .
    RET-IN-15
  • HY-145023
    RET-IN-5

    		RET Cancer
    RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC50s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18) .
    RET-IN-5
  • HY-120937
    DC4 Crosslinker

    		Others Others
    DC4 Crosslinker is a stable crosslinking reagent with improved activity and solubility. DC4 Crosslinker is labile cleavable with collision-induced dissociation (CID), that will be fragmented into four rearrange products containing mobilized protons .
    DC4 Crosslinker
  • HY-143545
    RET-IN-8

    		RET Cancer
    RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer .
    RET-IN-8
  • HY-114410
    CCI-006

    		Mitochondrial Metabolism Cancer
    CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of MLL-r leukemia cells .
    CCI-006
  • HY-151672
    Biotin-TEG-ATFBA

    		ADC Linker Others
    Biotin-TEG-ATFBA is a click chemistry reagent containing a perfluorophenylazide group. Biotin-TEG-ATFBA forms a highly stable azene intermediate that undergoes insertion and addition reactions (non-intermolecular rearrangement) in moderate to good yields after photolysis.
    Biotin-TEG-ATFBA
  • HY-145574
    Iruplinalkib

    WX-0593

    		 Anaplastic lymphoma kinase (ALK) ROS Kinase Cancer
    Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement .
    Iruplinalkib
  • HY-136175
    Revumenib
    5+ Cited Publications

    SNDX-5613

    		 Epigenetic Reader Domain Cancer
    Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
    Revumenib
  • HY-131003A
    Taletrectinib free base

    DS-6051b free base; AB-106 free base; IBI-344 free base

    		 ROS Kinase Cancer
    Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
    Taletrectinib free base
  • HY-131003
    Taletrectinib
    1 Publications Verification

    DS-6051b; AB-106; IBI-344

    		 ROS Kinase Cancer
    Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
    Taletrectinib
  • HY-124906
    JAMI1001A

    		iGluR Neurological Disease
    JAMI1001A is a positive allosteric modulator of AMPA receptor. JAMI1001A efficaciously modulates AMPA receptor deactivation and desensitization of both flip and flop receptor isoforms .
    JAMI1001A
  • HY-P3245
    HXR9

    		Apoptosis Cancer
    HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
    HXR9
  • HY-P3245A
    HXR9 hydrochloride

    		Apoptosis Cancer
    HXR9 hydrochloride is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 hydrochloride antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 hydrochloride selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
    HXR9 hydrochloride
  • HY-16993
    OICR-9429
    Maximum Cited Publications
    7 Publications Verification

    		 Histone Methyltransferase Apoptosis Cancer
    OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
    OICR-9429
  • HY-N10771
    (R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol

    		Others Others
    (R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol (compound 48) is a catechol compound. (R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol involves in bioinspired synthesis of rearranged abietane diterpenes, related to pygmaeocins .
    (R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol
  • HY-N12561
    Pestanoid A

    		ERK p38 MAPK JNK Others
    Pestanoid A is a rearranged pimarane diterpenoid osteoclastogenesis inhibitor with an IC50 of 4.2 μM. Pestanoid A can be isolated from the marine mesophotic zone chalinidae sponge-associated fungus, Pestalotiopsis sp. NBUF145. Pestanoid A inhibits the receptor activator of NF-kB ligand-induced MAPK and NF-κB signaling by suppressing the phosphorylation of ERK1/2-JNK1/2-p38 MAPKs and NF-κB nuclear translocation. Pestanoid A can be used for the study of osteoporosis .
    Pestanoid A
  • HY-144429
    TRPC5-IN-4

    		TRP Channel Metabolic Disease
    TRPC5-IN-4 is potent and safe TRPC inhibitor with IC50 value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD) .
    TRPC5-IN-4
  • HY-N6727
    Gliotoxin

    Aspergillin

    		 Apoptosis PKA NF-κB Bacterial Fungal Antibiotic Infection Inflammation/Immunology Cancer
    Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
    Gliotoxin
  • HY-12843
    Bohemine
    1 Publications Verification

    		 CDK ERK Cancer
    Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .
    Bohemine
  • HY-116116
    Tafetinib

    SIM010603

    		 c-Kit RET VEGFR Cancer
    Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
    Tafetinib
  • HY-151292
    Antitumor agent-74

    		DNA/RNA Synthesis Cancer
    Antitumor agent-74 (compound 13da) is a quinoxalines derivative, an antitumor agent. Antitumor agent-74 exhibits more potent efficacy on tumor inhibition, mixed with regioisomer Antitumor agent-75 (HY-151295, compound 14 da) (mriBIQ 13da/14da). mriBIQ 13da/14da attests cell cycle at S phase, inhibits DNA synthesis, and induces mithochondrial apoptosis .
    Antitumor agent-74

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: